Biogen Stock Rises After Earnings, Jump in Sales of Alzheimer’s Drug
Biogen stock moved higher after the biopharmaceutical company reported better-than-expected earnings and a hefty increase in sales of its Alzheimer’s drug. Biogen reported first-quarter adjusted earnings of $3.67 a share from revenue of $2.29 billion. Optimistic commentary from Biogen regarding its Alzheimer’s treatment Leqembi contributed to Wednesday’s gain.